RecruitingSolid Tumor, Adult
Prospective Cohort With Clinic-biologic Database of Patients Treated by Immunotherapy
Eligible age
18+ yrs
Accepts
All genders
Locations
0 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
ImmuCCo-1905 is a monocentric interventional study on patients treated by immunotherapy, which consist in establishment of a prospective clinic-biologic database over 5 years, associated with a biobank. This database will allow carrying out works aiming at assessing immunotherapy in real life situation.
Sponsor: Centre Oscar Lambret
You may qualify if…
- ✓ Age ≥ 18 years
- ✓ Beginning a first immunotherapy by immune checkpoint inhibitor - anti-PD1 (Programmed cell Death protein-1), anti-PDL1 (Programmed cell Death protein-1 ligand), anti-CTLA4 (Cytotoxic T-Lymphocyte associated protein 4), as monotherapy or in combination, in the Centre Oscar Lambret (COL)
- ✓ In neo-adjuvant, adjuvant, recurrence or metastatic situation
- ✓ Suffering from solid tumor histologically documented
- ✓ Signed written informed consent
- ✓ Patient covered by the French " "Social Security" regime If the patient is already enrolled in clinical trial involving immunotherapy, the agreement of the sponsor of this new trial will be sought before his/her inclusion.
You may not qualify if…
- ✕ Pregnant or breastfeeding women
- ✕ Patient already treated by immunotherapy by immune checkpoint inhibitor
- ✕ Person under guardianship
- ✕ Inability to comply with medical follow-up of the trial (geographical, social or psychic reasons)
Source: ClinicalTrials.gov · NCT05223608 · last updated 2026-03-30